In Vivo CAR-T Development Service with Lentivirus Technology

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Are you currently challenged by the complex logistics, high manufacturing costs, and the clinical burden of lymphodepletion associated with ex vivo cell therapy? Creative Biolabs' In vivo CAR-T Development with Lentivirus Technology directly engineers T cells inside the body, bypassing conventional ex vivo manipulation. By utilizing optimized vector design and bioprocessing, we enhance targeting specificity, improve safety, and accelerate the translational pathway from concept to clinic. We provide end-to-end solutions to efficiently advance your CAR-T candidates toward clinical application with reduced risk and streamlined development.

Introduction

Lentiviral vector technology serves as a highly efficient gene delivery platform that leverages the structural properties of the Retroviridae family to enable stable integration of exogenous genes into the host genome, thereby facilitating sustained and stable transgene expression. This technology allows for the in vivo generation of CAR-T cells through targeted delivery of chimeric antigen receptor genes to host T lymphocytes, empowering them to specifically recognize and eliminate tumor cells. This strategy opens up novel therapeutic avenues and future directions for cancer immunotherapy.

Fig.1 Integrated upstream and downstream processing for lentiviral vectors. (OA Literature) Fig.1 Full-scale manufacturing of clinical-grade lentiviral vectors.¹

In vivo CAR-T Development with Lentivirus Technology at Creative Biolabs

Creative Biolabs' In vivo CAR-T Development with Lentivirus Technology engineers targeted lentiviral vectors capable of direct in vivo CAR gene delivery, eliminating the need for complex ex vivo manufacturing. Our platform integrates surface engineering for precise T cell targeting, inducible control systems for enhanced safety, and scalable production processes, enabling the development of non-lymphodepleting, viable therapies with accelerated translational pathways.

What We Can Offer

We offer a comprehensive suite of advanced lentiviral vector solutions for in vivo CAR-T development. Our platform integrates precision-targeted vector design with robust safety-enhanced strategies, including T cell specific transduction and built-in biosafety controls, to enable efficient and secure generation of CAR-T cells directly within the patient.

Featured services of in vivo CAR-T development with lentivirus technology at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Antigen Identification: The specific tumor-associated antigen (TAA) or cell surface marker the CAR should recognize.
CAR Construct Sequence: The full sequence of the CAR, including the scFv, hinge, transmembrane, and co-stimulatory domains.
Desired Cell Tropism: Specification of the target immune cell population to guide vector surface engineering.

Key Steps:

Workflow of in vivo CAR-T development with lentivirus technology at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Final Vector: A high-titer, purified, and sterile batch of the lentiviral vector platform.
Certificate of Analysis (CoA): Detailed documentation validating the vector's identity, purity, sterility, and measured potency/titer.

Key Advantages

Precision-Targeted Vector Engineering: Our bespoke lentiviral vector design incorporates surface-displayed targeting moieties to enable highly specific in vivo transduction of defined immune cell populations—a critical capability for non-lymphodepleting therapeutic strategies.
Scalable, High-Titer Bioprocessing: We deliver integrated process development and pilot-scale production using closed-system, single-use technologies. Through optimized media and advanced downstream purification (e.g., chromatography, ultracentrifugation), we consistently generate high-purity vector batches ready for use.
Comprehensive Functional & Potency Profiling: We establish client-customized analytical and functional QC strategies, including precise infectious titer quantification, CAR expression stability evaluation, and in vitro potency assays (e.g., tumor cell killing).

FAQ

How does your in vivo CAR-T platform overcome the need for toxic preconditioning chemotherapy?

Our platform utilizes proprietary surface-engineered lentiviral vectors that are highly targeted to specific circulating immune cells. This precision ensures that the CAR gene is delivered with high efficiency and low off-target transduction, allowing the patient's existing immune system to be reprogrammed without the need for lymphodepleting drugs.

What measures are in place to prevent non-specific transduction or off-target effects in vivo?

We employ multiple layers of safety control. Firstly, the vector is engineered with de-targeting mutations to prevent non-specific tissue uptake. Secondly, we incorporate targeting moieties for cellular specificity. Finally, advanced constructs include inducible promoter systems which act as an 'ON switch,' ensuring the therapeutic payload is only expressed when the transduced cell encounters the target tumor antigen, significantly enhancing safety.

Why Choose Us?

Creative Biolabs pioneers in vivo CAR-T development through advanced lentiviral vector engineering. Our platform uniquely eliminates the need for toxic lymphodepletion via proprietary fusogens, integrates antigen-inducible control systems to prevent T-cell exhaustion, and delivers scalable vector production. This integrated approach ensures safer, more controllable, and commercially viable therapies.

Customer Reviews

"Using Creative Biolabs' In vivo CAR-T Development with Lentivirus Technology in our research has significantly improved the safety profile of our construct by integrating an activation-inducible promoter, solving our previous systemic toxicity concerns." Dr. Js W****n.

"Leveraging advanced expertise in closed-system bioprocessing, Creative Biolabs significantly accelerated our transition from research-scale to a robust, scalable production platform. This collaboration directly resolved the pivotal challenge of manufacturing high-titer vectors for commercial application." Pl S****r, Ph.D.

"The rigor in their functional characterization and titration assays, specifically their optimized ultracentrifugation method, gave us the confidence in our final product's potency needed for regulatory submission, a level of detail we couldn't achieve internally." Ma A****i, Principal Scientist.

How to contact us?

Leverage our expertise in precision lentiviral vector engineering to overcome key challenges in safety, specificity, and scalability for your in vivo CAR-T program. Partner with us to design targeted, efficient, and viable therapies—contact our specialist team today to accelerate your candidate from concept to clinic.

Reference

Labbé, Roman P et al. "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives." Viruses vol. 13,8 1528. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/v13081528.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.